Transplant Options for Patients with Hodgkin Disease
Summary:
Transplant Options for Patients with Hodgkin Disease
Presented by Matthew Matasar MD, Assistant Member of Lymphoma and Adult BMT Services, and Medical Director of the Lymphoma Survivorship Clinic at Memorial Sloan Kettering Cancer Center
Run time: 56 minute presentation, followed by 34 minute Q&A
Made possible, in part, by a grant from Seattle Genetics
Dr. Matasar discusses:
- History of Hodgkin lymphoma
- Reed Sternberg cells
- Incidence (number of new cases) of Hodgkin lymphoma each year
- Number of Hodgkin lymphoma survivors
- Signs and symptoms of Hodgkin lymphoma
- Stages of Hodgkin lymphoma
- Treatment of newly diagnosed Hodgkin lymphoma
- Treatment of relapsed or refractory Hodgkin lymphoma
- Autologous stem cell transplant for Hodgkin lymphoma (transplant using your own cells)
- Allogeneic stem cell transplant for Hodgkin lymphoma (transplant using donor cells)
- Factors to consider when choosing between an autologous or allogeneic transplant
- Current treatment options and results for patients with relapsed or refractory Hodgkin lymphoma
- New treatment options for patients with relapsed or refractory Hodgkin lymphoma including brentuximab, nivolumab and pembrolizumab
- Risks and benefits of transplant for patients with Hodgkin lymphoma
- Survivorship care plan for patients with Hodgkin lymphoma
This article is in these categories:
